Who
Matthew C. Kapusta
CEO, Managing Director
Company insider
Files Form 4 as: CEO, Managing Director, uniQure; Director, Decibel Therapeutics; SVP, Business Development, AngioDynamics.
In numbers
- Trades disclosed
- 246
- Buys
- 2
- Sells
- 66
- Bought
- $25K
- Sold
- $63.0M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 2 Feb 2012
- Last trade
- 2 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jul 2026filed 7 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code M | $409K21,082 at $19.39 | filing |
| 2 Jul 2026filed 7 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $409K9,200 at $44.43 | filing |
| 2 Jul 2026filed 7 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $195K4,282 at $45.43 | filing |
| 2 Jul 2026filed 7 Jul 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,082 at $0.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $349K7,600 at $45.89 | filing |
| 2 Jul 2026filed 7 Jul 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,082 at $0.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code M | $409K21,082 at $19.39 | filing |
| 2 Jul 2026filed 7 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $409K9,200 at $44.43 | filing |
| 2 Jul 2026filed 7 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $195K4,282 at $45.43 | filing |
| 2 Jul 2026filed 7 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $349K7,600 at $45.89 | filing |
| 25 Jun 2026filed 26 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code M | $911K28,716 at $31.71 | filing |
| 25 Jun 2026filed 26 Jun 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,716 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $1.4M28,716 at $50.02 | filing |
| 25 Jun 2026filed 26 Jun 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,716 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code M | $911K28,716 at $31.71 | filing |
| 25 Jun 2026filed 26 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $1.4M28,716 at $50.02 | filing |
| 24 Jun 2026filed 26 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code M | $131K4,128 at $31.71 | filing |
| 24 Jun 2026filed 26 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $335K6,696 at $50.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,128 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,128 at $0.00 | filing |
News
Reviewing uniQure (NASDAQ:QURE) & Arvinas (NASDAQ:ARVN)QURE · tickerreport.com · 25 Oct 2026uniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $53.25QURE · dailypolitical.com · 24 Oct 2026ProKidney (NASDAQ:PROK) vs. uniQure (NASDAQ:QURE) Financial SurveyQURE · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Matthew C. Kapusta; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.